Alfred E. Tiefenbacher (GmbH & Co. KG)   Report issue

For profit Phase 3
Founded: Frankfurt Germany (1963)
Status: No NME R&D (1963)

Organization Overview

First Clinical Trial
2009
NCT00878917
First Marketed Drug
2021
posaconazole (noxafil)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

AET PHARMA

Active Ingredients

Marketed Drugs (2)

leflunomide (arava) (2021)

posaconazole (noxafil) (2021)

Drugs in Phase 3 Trials (1)

dorzolamide (trusopt) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glaucoma (Phase 3)

Glaucoma, Open-Angle (Phase 3)

Hypertension (Phase 3)

Ocular Hypertension (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1